Artwork

Innhold levert av Hopkins Biotech Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Hopkins Biotech Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Miranda Broz - Developing Cancer Immunotherapies

38:43
 
Del
 

Manage episode 286783982 series 2788785
Innhold levert av Hopkins Biotech Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Hopkins Biotech Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Miranda Broz, PhD is the Scientific Associate Director of Discovery Myeloid Biology at Bristol Myers Squibb’s R&D site in Redwood City, California. Miranda and her team explores parts of the tumor microenvironment (TME) - including regulatory T cells, stromal cells and myeloid antigen presenting cells - to develop novel treatment options that will benefit patients with difficult-to-treat cancers. In this episode, Miranda shares her journey from PhD to Scientific Officer at Pionyr Immunotherapeutics - an immuno-oncology focused startup that was founded based on her thesis work at UCSF - to her current role at Bristol Myers Squibb. We discuss the various learning curves that she scaled as a growing industry scientist, the skills that she developed in order to effectively lead teams through pre-clinical drug development, and the enriching institutional support that Bristol Myers Squibb offers its employees. Furthermore, we briefly discuss the history of cancer immunotherapies as the field has matured over the past few decades, the challenges that still exist for the field, and the approach that Miranda & her colleagues are taking to overcome those challenges.

Hosted by Roshan Chikarmane and Jenna Glatzer.

  continue reading

84 episoder

Artwork
iconDel
 
Manage episode 286783982 series 2788785
Innhold levert av Hopkins Biotech Podcast. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Hopkins Biotech Podcast eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Miranda Broz, PhD is the Scientific Associate Director of Discovery Myeloid Biology at Bristol Myers Squibb’s R&D site in Redwood City, California. Miranda and her team explores parts of the tumor microenvironment (TME) - including regulatory T cells, stromal cells and myeloid antigen presenting cells - to develop novel treatment options that will benefit patients with difficult-to-treat cancers. In this episode, Miranda shares her journey from PhD to Scientific Officer at Pionyr Immunotherapeutics - an immuno-oncology focused startup that was founded based on her thesis work at UCSF - to her current role at Bristol Myers Squibb. We discuss the various learning curves that she scaled as a growing industry scientist, the skills that she developed in order to effectively lead teams through pre-clinical drug development, and the enriching institutional support that Bristol Myers Squibb offers its employees. Furthermore, we briefly discuss the history of cancer immunotherapies as the field has matured over the past few decades, the challenges that still exist for the field, and the approach that Miranda & her colleagues are taking to overcome those challenges.

Hosted by Roshan Chikarmane and Jenna Glatzer.

  continue reading

84 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett